IP Library Granted Patent US 8,299,018
Granted Patent B2
US 8,299,018 · App. 12/333,499 · Granted Oct 30, 2012

Proteins with an attached short peptide of acidic amino acids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,299,018
App. No.
12/333,499
Granted
Oct 30, 2012
Kind
B2
Abstract

Disclosed are a fusion protein comprising enzyme N-acetylgalactosamine-6-sulfate sulfatase and a short peptide consisting of 4-15 acidic amino acids attached to the enzyme on its N-terminal side, a pharmaceutical composition containing the fusion protein, and a method for treatment of type A Morquio disease using the fusion protein. Compared with the native enzyme protein, the fusion protein exhibits higher transferability to bone tissues and improved, higher stability in the blood.

Claims (6)

1. A method for treatment of type A Morquio disease, comprising administering to a human patient therewith a therapeutically effective amount of a fusion protein consisting of SEQ ID NO: 7.

2. The method for treatment according to claim 1 , wherein the fusion protein consists of amino acid residues 21-528 of SEQ ID NO: 7.

3. The method for treatment according to claim 1 , wherein the fusion protein is administered intravenously, subcutaneously or intramuscularly.

4. A method for treatment of type A Morquio disease, comprising administering to a human patient therewith a therapeutically effective amount of a pharmaceutical preparation consisting of SEQ ID NO: 7.

5. The method for treatment according to claim 4 , wherein the pharmaceutical preparation is administered intravenously, subcutaneously or intramuscularly.

6. The method for treatment according to claim 4 , wherein the fusion protein consists of amino acid residues 20-528 of SEQ ID NO: 7.

Assignments (1)
SECURITY INTEREST Recorded Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →